SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011; 117: 26-38.
  • 2
    Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009; 2009: 542-551.
  • 3
    Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009; 114: 1469-1476.
  • 4
    Leonard JP, Williams ME, Goy A, et al. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma. 2009; 9: 267-277.
  • 5
    Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev. 2011; 240: 141-159.
  • 6
    Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine. 2010; 49: 1-9.
  • 7
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4: 499-511.
  • 8
    Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst. 2006; 98: 574-575.
  • 9
    Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med. 2009; 9: 324-335.
  • 10
    Zhao WJ, Xi LY, Ma L. [Effect of Penicillium marneffei on TLR-2, TLR-4, and Dectin-1 expression and TNF-alpha production in macrophage.] Nan Fang Yi Ke Da Xue Xue Bao. 28: 37-40, 2008.
  • 11
    Tichomirowa M, Theodoropoulou M, Lohrer P, et al. Bacterial endotoxin (lipopolysaccharide) stimulates interleukin-6 production and inhibits growth of pituitary tumour cells expressing the toll-like receptor 4. J Neuroendocrinol. 2005; 17: 152-160.
  • 12
    Chicoine MR, Zahner M, Won EK, et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 60: 372-380, 2007; discussion 381.
  • 13
    Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res. 2007; 67: 10519-10527.
  • 14
    Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011; 60: 1211-1220.
  • 15
    Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009; 28: 4353-4363.
  • 16
    Bao H, Lu P, Li Y, et al. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol Ther. 2011; 11: 58-67.
  • 17
    Xu Y, Zhao Y, Huang H, et al. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol. 2010; 150: 543-553.
  • 18
    Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011; 71: 2466-2475.
  • 19
    Song EJ, Kang MJ, Kim YS, et al. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med. 2011; 28: 115-119.
  • 20
    Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007; 110: 1587-1594.
  • 21
    Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood. 2006; 107: 2432-2439.
  • 22
    Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem. 2011; 18: 2257-2262.
  • 23
    Sahoo M, Ceballos-Olvera I, del Barrio L, Re F. Role of the inflammasome, IL-1beta, and IL-18 in bacterial infections. ScientificWorldJournal. 2011; 11: 2037-2050.
  • 24
    Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett. 2009; 14: 248-272.
  • 25
    Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009; 9: 57-63.
  • 26
    He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007; 44: 2850-2859.
  • 27
    Nunez NG, Andreani V, Crespo MI, et al. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012; 72: 592-603.
  • 28
    Toshchakov VY, Szmacinski H, Couture LA, Lakowicz JR, Vogel SN. Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface. J Immunol. 2011; 186: 4819-4827.
  • 29
    Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2010; 11: 141-147.
  • 30
    Lysakova-Devine T, Keogh B, Harrington B, et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol. 2010; 185: 4261-4271.
  • 31
    Tang B, Xiao B, Liu Z, et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 2010; 584: 1481-1486.